Major players are focused on enhancing the business capabilities by their approach towards acquisition and new product launches to help the company increase the customer base of the company.

In 2020, Moderna a biotechnology company focused on drug discovery, drug development, and vaccine technologies received the approval from U.S. Food and Drug Administration’s (FDA) for the emergency use of mRNA-1273 against novel coronavirus. This is expected to help the company to market and sell the therapy in US market.

In 2020, the company received award from Defense Advanced Research Projects Agency of US$ 56 Million in order to enable small-scale, rapid mobile manufacturing of nucleic acid vaccines and therapeutics. This will help the company to enhance the R&D capabilities and increase the product portfolio.

In 2020, Gilead Sciences, Inc. is a research-based biopharmaceutical company acquired Immunomedics. This acquisition will help the company to enhance the business presence and increase the product offering capabilities.

In 2020, the company signed a definitive merger agreement with Forty Seven, Inc. a clinical-stage immuno-oncology company. This merger is expected to help the company to enhance the product portfolio.

Government of developing countries is spending high on the development of healthcare infrastructure, changing regulatory scenario, and inclination towards strengthening the regional manufacturing capabilities are among other factors expected to boost the growth of cytokine storm therapy market. In addition, favorable business policies and emergence of small & mid-size enterprises with innovative solutions are factors expected to impact the growth of target market.

Factors such as high cost associated to therapy and stringent government regulations related to product approval are expected to hamper the growth of global cytokine storm therapy market. In addition, lack of developed infrastructure in developing countries is expected to limit the R&D activities which can challenge the growth of cytokine storm therapy market.

Increasing investment by major players for development of innovative therapy and early product approvals from the government as preventive measure are factors expected to create new opportunities for players operating in cytokine storm therapy market. In addition, increasing public-private partnership in order to enhance the business is expected to support the revenue transaction of target market.

Segment Analysis by Region

The market in North America is expected to account for major revenue share in the cytokine storm therapy market due to high patient pool suffering from diseases such as Coronavirus and Influenza. In addition, availability of advanced infrastructure for R&D activities and introduction of novel products are expected to augment the growth of target market. Presence of large number of players operating in the country and high investment for drug discovery will support the growth of target market.

Competitive Landscape      

The global market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

Report coverage

Cytokine Storm Therapy Market Segment Analysis, 2019

The global cytokine storm therapy market is segmented into disease, treatment and distribution channel. The diseases segment is bifurcated into Viral (COVID-19, Influenza, Dengue, Ebola), Multiple sclerosis, and Sepsis. Among the diseases the viral segment is expected to account for significant revenue share. The distribution channel segment is divided into hospitals pharmacies, retailer pharmacies, and online pharmacies. Among the distribution channel the hospitals pharmacies segment is expected to account for major revenue share in the global market.

The players profiled in the report are Moderna, Gilead Sciences, Pfizer, Roche, Regeneron Pharmaceuticals Biocon, CytoSorbents, Johnson & Johnson, Sanofi, Novartis, Quotient Sciences, and AstraZeneca.

Market Segmentation

Market By Diseases

Viral (COVID-19, Influenza, Dengue, Ebola)

Multiple sclerosis

Sepsis

Market By Treatment

Immunomodulatory therapy (Anti-inflammatory drugs, Biological/ chemical modifiers, Immunoglobin therapy)

Plasma therapy

Stem-cell therapy

Cytokine absorption devices (extracorporeal membrane oxygenation (ECMO))

Market By Distribution Channel

Hospitals pharmacies

Retailer pharmacies

Online pharmacies

Market By Region

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC
• South Africa
• Rest of Middle East & Africa